{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:34:56Z","timestamp":1791304496198,"version":"4.3.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04736-5","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:04:02Z","timestamp":1771333442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monoclonal antibodies in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-8970","authenticated-orcid":false,"given":"Paulo S.","family":"de Melo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"de Oliveira Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Maria Barreto","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Antonio Pereira","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Lordelo San","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"4736_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","volume":"387 7","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica spectrum disorder. N Engl J Med. 2022;387 7:631\u20139. https:\/\/doi.org\/10.1056\/NEJMra1904655.","journal-title":"N Engl J Med"},{"key":"4736_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","volume":"44 6","author":"S Bagherieh","year":"2023","unstructured":"Bagherieh S, Afshari-Safavi A, Vaheb S, Kiani M, Ghaffary EM, Barzegar M, et al. Worldwide prevalence of neuromyelitis Optica spectrum disorder (NMOSD) and neuromyelitis Optica (NMO): a systematic review and meta-analysis. Neurol Sci. 2023;44 6:1905\u201315. https:\/\/doi.org\/10.1007\/s10072-023-06617-y.","journal-title":"Neurol Sci"},{"key":"4736_CR3","doi-asserted-by":"publisher","first-page":"103465","DOI":"10.1016\/j.autrev.2023.103465","volume":"22 12","author":"P Siriratnam","year":"2023","unstructured":"Siriratnam P, Huda S, Butzkueven H, van der Walt A, Jokubaitis V, Monif M. A comprehensive review of the advances in neuromyelitis Optica spectrum disorder. Autoimmun Rev. 2023;22 12:103465. https:\/\/doi.org\/10.1016\/j.autrev.2023.103465.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"4736_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, H\u00e4u\u00dfler V, et al. Update on the diagnosis and treatment of neuromyelitis Optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis Optica study group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376. https:\/\/doi.org\/10.1007\/s00415-023-11910-z.","journal-title":"J Neurol"},{"key":"4736_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","volume":"13 1","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gold R. Present and future therapies in neuromyelitis Optica spectrum disorders. Neurotherapeutics. 2016;13 1:70\u201383. https:\/\/doi.org\/10.1007\/s13311-015-0400-8.","journal-title":"Neurotherapeutics"},{"key":"4736_CR6","doi-asserted-by":"publisher","first-page":"105452","DOI":"10.1016\/j.msard.2024.105452","volume":"83","author":"DL San Martin","year":"2024","unstructured":"San Martin DL, Fukuda TG, Nascimento TS, Silva MB, Filho MBP, Forcadela M, et al. Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis Optica spectrum disorder: A cohort study. Mult Scler Relat Disord. 2024;83:105452. https:\/\/doi.org\/10.1016\/j.msard.2024.105452.","journal-title":"Mult Scler Relat Disord"},{"key":"4736_CR7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4736_CR8","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane; 2024. Available from https:\/\/www.cochrane.org\/handbook."},{"issue":"2","key":"4736_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis Optica spectrum disorders. Neurology. 2015;85(2):177\u201389. https:\/\/doi.org\/10.1212\/wnl.0000000000001729.","journal-title":"Neurology"},{"key":"4736_CR10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4736_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80 1","author":"FIRTH D","year":"1993","unstructured":"FIRTH D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80 1:27\u201338. https:\/\/doi.org\/10.1093\/biomet\/80.1.27.","journal-title":"Biometrika"},{"key":"4736_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22 4","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22 4:153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"4736_CR13","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1007\/s00415-023-11641-1","volume":"270 6","author":"Z Yin","year":"2023","unstructured":"Yin Z, Qiu Y, Duan A, Fang T, Chen Z, Wu J, et al. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis Optica spectrum disorder: a bayesian network meta-analysis. J Neurol. 2023;270 6:2950\u201363. https:\/\/doi.org\/10.1007\/s00415-023-11641-1.","journal-title":"J Neurol"},{"key":"4736_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","volume":"35","author":"W Huang","year":"2019","unstructured":"Huang W, Wang L, Zhang B, Zhou L, Zhang T, Quan C. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis Optica spectrum disorders: A systematic review and network meta-analysis. Mult Scler Relat Disord. 2019;35:246\u201352. https:\/\/doi.org\/10.1016\/j.msard.2019.08.009.","journal-title":"Mult Scler Relat Disord"},{"key":"4736_CR15","doi-asserted-by":"publisher","first-page":"102166","DOI":"10.1016\/j.msard.2020.102166","volume":"43","author":"T Xue","year":"2020","unstructured":"Xue T, Yang Y, Lu Q, Gao B, Chen Z, Wang Z. Efficacy and safety of monoclonal antibody therapy in neuromyelitis Optica spectrum disorders: evidence from randomized controlled trials. Mult Scler Relat Disord. 2020;43:102166. https:\/\/doi.org\/10.1016\/j.msard.2020.102166.","journal-title":"Mult Scler Relat Disord"},{"key":"4736_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68 8","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis Optica. Neurology. 2007;68 8:603\u20135. https:\/\/doi.org\/10.1212\/01.wnl.0000254502.87233.9a.","journal-title":"Neurology"},{"key":"4736_CR17","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/acn3.51451","volume":"8 10","author":"J Giovannelli","year":"2021","unstructured":"Giovannelli J, Ciron J, Cohen M, Kim H-J, Kim S-H, Stellmann J-P, et al. A meta-analysis comparing first-line immunosuppressants in neuromyelitis Optica. Ann Clin Transl Neurol. 2021;8 10:2025\u201337. https:\/\/doi.org\/10.1002\/acn3.51451.","journal-title":"Ann Clin Transl Neurol"},{"key":"4736_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1352458515587752","volume":"22 3","author":"IH Jeong","year":"2016","unstructured":"Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis Optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22 3:329\u201339. https:\/\/doi.org\/10.1177\/1352458515587752.","journal-title":"Mult Scler"},{"key":"4736_CR19","doi-asserted-by":"publisher","unstructured":"Zhou J, Yang X, Wang X, Li B, Xu Y, Zhang H, et al. Immunotherapy for neuromyelitis Optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. Front Neurol. 2025;16\u20132025. https:\/\/doi.org\/10.3389\/fneur.2025.1559118.","DOI":"10.3389\/fneur.2025.1559118"},{"key":"4736_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71 3","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71 3:324\u201330. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5699.","journal-title":"JAMA Neurol"},{"key":"4736_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","volume":"385","author":"Y Yang","year":"2018","unstructured":"Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis Optica spectrum disorder. J Neurol Sci. 2018;385:192\u20137. https:\/\/doi.org\/10.1016\/j.jns.2017.12.034.","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"4736_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neurol.2024.01.008","volume":"181","author":"S Demuth","year":"2025","unstructured":"Demuth S, Collongues N. Disease-modifying treatments for neuromyelitis Optica spectrum disorder in the context of a new generation of biotherapies. Rev Neurol (Paris). 2025;181(1\u20132):42\u201351. https:\/\/doi.org\/10.1016\/j.neurol.2024.01.008.","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"4736_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","volume":"11","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, et al. Network Meta-analysis of food and drug Administration-approved treatment options for adults with Aquaporin-4 Immunoglobulin G-positive neuromyelitis Optica spectrum disorder. Neurol Ther. 2022;11(1):123\u201335. https:\/\/doi.org\/10.1007\/s40120-021-00295-8.","journal-title":"Neurol Ther"},{"key":"4736_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","volume":"176 2","author":"S Jarius","year":"2014","unstructured":"Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, Immunopathogenesis and treatment. Clin Exp Immunol. 2014;176 2:149\u201364. https:\/\/doi.org\/10.1111\/cei.12271.","journal-title":"Clin Exp Immunol"},{"key":"4736_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neurol.2024.01.008","volume":"181 1","author":"S Demuth","year":"2025","unstructured":"Demuth S, Collongues N. Disease-modifying treatments for neuromyelitis Optica spectrum disorder in the context of a new generation of biotherapies. Rev Neurol. 2025;181 1:42\u201351. https:\/\/doi.org\/10.1016\/j.neurol.2024.01.008.","journal-title":"Rev Neurol"},{"key":"4736_CR26","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264 10","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264 10:2088\u201394. https:\/\/doi.org\/10.1007\/s00415-017-8596-7.","journal-title":"J Neurol"},{"key":"4736_CR27","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1212\/nxi.0000000000000626","volume":"6 6","author":"T Yeo","year":"2019","unstructured":"Yeo T, Probert F, Jurynczyk M, Sealey M, Cavey A, Claridge TDW, et al. Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling. Neurol Neuroimmunol Neuroinflamm. 2019;6 6:e626. https:\/\/doi.org\/10.1212\/nxi.0000000000000626.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4736_CR28","unstructured":"Pharmacoeconomic Review. Inebilizumab (Uplizna): therapeutic area: neuromyelitis Optica spectrum disorders: CADTH reimbursement review. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health."},{"key":"4736_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40259-025-00729-x","volume":"39 4","author":"AH Holian","year":"2025","unstructured":"Holian AH, Weinshenker BG. Emerging role of targeted monoclonal antibodies in neuromyelitis Optica spectrum disorders. BioDrugs. 2025;39 4:573\u201389. https:\/\/doi.org\/10.1007\/s40259-025-00729-x.","journal-title":"BioDrugs"},{"key":"4736_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","volume":"33","author":"AI Espiritu","year":"2019","unstructured":"Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis Optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019;33:22\u201332. https:\/\/doi.org\/10.1016\/j.msard.2019.05.011.","journal-title":"Mult Scler Relat Disord"},{"key":"4736_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1352458515587752","volume":"22 3","author":"IH Jeong","year":"2016","unstructured":"Jeong IH, Park B, Kim S-H, Hyun J-W, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis Optica spectrum disorder using multifaceted endpoints. Multiple Scler J. 2016;22 3:329\u201339. https:\/\/doi.org\/10.1177\/1352458515587752.","journal-title":"Multiple Scler J"},{"key":"4736_CR32","doi-asserted-by":"publisher","first-page":"e70243","DOI":"10.1111\/ene.70243","volume":"32 6","author":"D Engels","year":"2025","unstructured":"Engels D, Rocchi C, Forcadela M, Siriratnam P, Ringelstein M, H\u00fcmmert MW, et al. Rituximab as First-Line compared to escalation immunotherapy is associated with lower disability accumulation in Aquaporin-4-IgG-Positive neuromyelitis Optica spectrum disorder: A multicenter cohort study from Germany and the united Kingdom. Eur J Neurol. 2025;32 6:e70243. https:\/\/doi.org\/10.1111\/ene.70243.","journal-title":"Eur J Neurol"},{"key":"4736_CR33","doi-asserted-by":"publisher","unstructured":"Silva GD, Ap\u00f3stolos-Pereira SL, Boaventura M, Paolilo RB, Matos A, Pitombeira MS, et al. Early rituximab versus escalating therapy in neuromyelitis optica: A cost and quality of life analysis. Multiple Scler Relat Disorders. 2024;92. https:\/\/doi.org\/10.1016\/j.msard.2024.106160.","DOI":"10.1016\/j.msard.2024.106160"},{"issue":"2","key":"4736_CR34","doi-asserted-by":"publisher","first-page":"e0229028","DOI":"10.1371\/journal.pone.0229028","volume":"15","author":"S Aungsumart","year":"2020","unstructured":"Aungsumart S, Apiwattanakul M. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis Optica spectrum disorder in thailand: economic evaluation and budget impact analysis. PLoS ONE. 2020;15(2):e0229028. https:\/\/doi.org\/10.1371\/journal.pone.0229028.","journal-title":"PLoS ONE"},{"key":"4736_CR35","doi-asserted-by":"publisher","first-page":"175628642513140","DOI":"10.1177\/17562864251314020","volume":"18","author":"HL Lee","year":"2025","unstructured":"Lee HL, Kang M, Seok JM, Kim BJ, Kim BJ. Comparison of treatment efficacy and cost-effectiveness of rituximab and oral agents among patients with neuromyelitis Optica spectrum disorders: a population-based cohort study. Ther Adv Neurol Disord. 2025;18:17562864251314020. https:\/\/doi.org\/10.1177\/17562864251314020.","journal-title":"Ther Adv Neurol Disord"},{"key":"4736_CR36","doi-asserted-by":"publisher","unstructured":"Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, et al. International Delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for Eculizumab, Inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4). https:\/\/doi.org\/10.1212\/nxi.0000000000200124.","DOI":"10.1212\/nxi.0000000000200124"},{"key":"4736_CR37","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","volume":"186 6","author":"L Bologna","year":"2011","unstructured":"Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011;186 6:3762\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1000303.","journal-title":"J Immunol"},{"key":"4736_CR38","doi-asserted-by":"publisher","first-page":"e152006","DOI":"10.1212\/wnl.0000000000011744","volume":"96","author":"N Collongues","year":"2021","unstructured":"Collongues N, Alves Do Rego C, Bourre B, Biotti D, Marignier R, da Silva AM, et al. Pregnancy in patients with AQP4-Ab, MOG-Ab, or Double-Negative neuromyelitis Optica disorder. Neurology. 2021;96:e152006\u201315. https:\/\/doi.org\/10.1212\/wnl.0000000000011744.","journal-title":"Neurology"},{"key":"4736_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/jnnp-2020-323982","volume":"92 1","author":"L Wang","year":"2020","unstructured":"Wang L, Zhou L, ZhangBao J, Huang W, Chang X, Lu C, et al. Neuromyelitis Optica spectrum disorder: pregnancy-related attack and predictive risk factors. J Neurol Neurosurg Psychiatry. 2020;92 1:53\u201361. https:\/\/doi.org\/10.1136\/jnnp-2020-323982.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"4736_CR40","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1212\/nxi.0000000000000453","volume":"5","author":"G Das","year":"2018","unstructured":"Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453. https:\/\/doi.org\/10.1212\/nxi.0000000000000453.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"4736_CR41","doi-asserted-by":"publisher","first-page":"rkaa074","DOI":"10.1093\/rap\/rkaa074","volume":"5","author":"K Perrotta","year":"2021","unstructured":"Perrotta K, Kiernan E, Bandoli G, Manaster R, Chambers C. Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series. Rheumatol Adv Pract. 2021;5(1):rkaa074. https:\/\/doi.org\/10.1093\/rap\/rkaa074.","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"4736_CR42","doi-asserted-by":"publisher","first-page":"e734","DOI":"10.1212\/NXI.0000000000000734","volume":"7","author":"JB Smith","year":"2020","unstructured":"Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflammation. 2020;7(4):e734. https:\/\/doi.org\/10.1212\/NXI.0000000000000734.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"4736_CR43","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1177\/1352458517740215","volume":"23 14","author":"E Shosha","year":"2017","unstructured":"Shosha E, Pittock SJ, Flanagan E, Weinshenker BG. Neuromyelitis Optica spectrum disorders and pregnancy: interactions and management. Mult Scler. 2017;23 14:1808\u201317. https:\/\/doi.org\/10.1177\/1352458517740215.","journal-title":"Mult Scler"},{"key":"4736_CR44","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","volume":"16 3","author":"Y Mao-Draayer","year":"2020","unstructured":"Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz Sand I, et al. Neuromyelitis Optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020;16 3:154\u201370. https:\/\/doi.org\/10.1038\/s41582-020-0313-y.","journal-title":"Nat Rev Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04736-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04736-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04736-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:52:49Z","timestamp":1774432369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04736-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4736"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04736-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript and consent to its submission and publication in BMC Neurology. All authors agree to be accountable for all aspects of the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}